{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T01:24:43Z","timestamp":1794273883572,"version":"4.9.0"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82388101"],"award-info":[{"award-number":["82388101"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of Shanghai Municipality","doi-asserted-by":"publisher","award":["20DZ2270800"],"award-info":[{"award-number":["20DZ2270800"]}],"id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012232","name":"National Key Clinical Specialty Discipline Construction Program of China","doi-asserted-by":"publisher","award":["2022ZZ01003"],"award-info":[{"award-number":["2022ZZ01003"]}],"id":[{"id":"10.13039\/501100012232","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"publisher","award":["P30EY007003"],"award-info":[{"award-number":["P30EY007003"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Key R&D Program of China","award":["2024YFB4710200"],"award-info":[{"award-number":["2024YFB4710200"]}]},{"name":"National Key R&D Program of China","award":["2024YFB4710205"],"award-info":[{"award-number":["2024YFB4710205"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s40265-026-02388-w","type":"journal-article","created":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T11:03:16Z","timestamp":1790247796000},"page":"1891-1911","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy and Safety of IGF-1 Receptor Inhibitors for Thyroid Eye Disease: Systematic Review and Meta-analysis of Randomized Controlled Trials"],"prefix":"10.1007","volume":"86","author":[{"given":"Haiyang","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zixiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sien Ping","family":"Chew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huijie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinwei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry J","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huifang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,24]]},"reference":[{"key":"2388_CR1","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/S2213-8587(25)00218-9","volume":"13","author":"TJ Smith","year":"2025","unstructured":"Smith TJ. Thyroid eye disease and the IGF-1 receptor. Lancet Diabetes Endocrinol. 2025;13:741\u20132. https:\/\/doi.org\/10.1016\/S2213-8587(25)00218-9.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2388_CR2","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1056\/NEJMra1510030","volume":"375","author":"TJ Smith","year":"2016","unstructured":"Smith TJ, Heged\u00fcs L. Graves\u2019 disease. N Engl J Med. 2016;375:1552\u201365. https:\/\/doi.org\/10.1056\/NEJMra1510030.","journal-title":"N Engl J Med"},{"key":"2388_CR3","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1111\/cen.15183","volume":"102","author":"MN Stan","year":"2025","unstructured":"Stan MN, Wagner LH, Rachmasari KN, Venker B, Arackal J, Wang J, et al. Epidemiology and management of moderate to severe thyroid eye disease in the United States: analysis of a healthcare claims database. Clin Endocrinol (Oxf). 2025;102:482\u20139. https:\/\/doi.org\/10.1111\/cen.15183.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2388_CR4","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/joim.13524","volume":"292","author":"L Bartalena","year":"2022","unstructured":"Bartalena L, Tanda ML. Current concepts regarding Graves\u2019 orbitopathy. J Intern Med. 2022;292:692\u2013716. https:\/\/doi.org\/10.1111\/joim.13524.","journal-title":"J Intern Med"},{"key":"2388_CR5","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.1007\/s40618-024-02332-3","volume":"47","author":"R Le Moli","year":"2024","unstructured":"Le Moli R, Naselli A, Giudice FL, Costanzo G, Frasca F, Belfiore A. Temporal trends in the clinical presentation of Graves\u2019 orbitopathy: a single\u2013center retrospective study. J Endocrinol Invest. 2024;47:2177\u201384. https:\/\/doi.org\/10.1007\/s40618-024-02332-3.","journal-title":"J Endocrinol Invest"},{"key":"2388_CR6","doi-asserted-by":"publisher","DOI":"10.1530\/EC-24-0259","volume":"13","author":"WKW Al-Badri","year":"2024","unstructured":"Al-Badri WKW, Jellema HM, Potvin ARGG, Van Nispen RMA, Bisschop PH, Saeed P. Psychological aspects of graves\u2019 ophthalmopathy. Endocr Connect. 2024;13:e240259. https:\/\/doi.org\/10.1530\/EC-24-0259.","journal-title":"Endocr Connect"},{"key":"2388_CR7","doi-asserted-by":"publisher","first-page":"3857","DOI":"10.1210\/jc.2012-2758","volume":"97","author":"ML Tanda","year":"2012","unstructured":"Tanda ML, Bartalena L. Efficacy and safety of orbital radiotherapy for Graves\u2019 orbitopathy. J Clin Endocrinol Metab. 2012;97:3857\u201365. https:\/\/doi.org\/10.1210\/jc.2012-2758.","journal-title":"J Clin Endocrinol Metab"},{"key":"2388_CR8","doi-asserted-by":"publisher","DOI":"10.1530\/ETJ-22-0189","volume":"11","author":"HB Burch","year":"2022","unstructured":"Burch HB, Perros P, Bednarczuk T, Cooper DS, Dolman PJ, Leung AM, et al. Management of thyroid eye disease: a consensus statement by the American thyroid association and the European thyroid association. Eur Thyroid J. 2022;11:e220189. https:\/\/doi.org\/10.1530\/ETJ-22-0189.","journal-title":"Eur Thyroid J."},{"key":"2388_CR9","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1007\/s40618-024-02304-7","volume":"47","author":"K Pelewicz","year":"2024","unstructured":"Pelewicz K, Mi\u015bkiewicz P. Glucocorticoid-induced adrenal insufficiency after therapy with intravenous methylprednisolone in patients with moderate-to-severe and active Graves\u2019 orbitopathy: assessment with a low-dose corticotropin test. J Endocrinol Invest. 2024;47:1987\u201394. https:\/\/doi.org\/10.1007\/s40618-024-02304-7.","journal-title":"J Endocrinol Invest"},{"key":"2388_CR10","doi-asserted-by":"publisher","first-page":"385","DOI":"10.3109\/01676830.2014.904378","volume":"33","author":"D Hersh","year":"2014","unstructured":"Hersh D, Kinnar M. Acute dysthyroid optic neuropathy exacerbated by orbital radiotherapy. Orbit. 2014;33:385\u20137. https:\/\/doi.org\/10.3109\/01676830.2014.904378.","journal-title":"Orbit"},{"key":"2388_CR11","doi-asserted-by":"publisher","first-page":"G43","DOI":"10.1530\/EJE-21-0479","volume":"185","author":"L Bartalena","year":"2021","unstructured":"Bartalena L, Kahaly GJ, Baldeschi L, Dayan CM, Eckstein A, Marcocci C, et al. The 2021 European Group on Graves\u2019 Orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves\u2019 orbitopathy. Eur J Endocrinol. 2021;185:G43-67. https:\/\/doi.org\/10.1530\/EJE-21-0479.","journal-title":"Eur J Endocrinol"},{"key":"2388_CR12","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1038\/s41433-025-03845-8","volume":"39","author":"AG Abumohssin","year":"2025","unstructured":"Abumohssin AG, Alshareef RA, Aljohani S, Alqutub A, Alqutub A. Comparative efficacy and safety of rituximab, tocilizumab, and teprotumumab in graves\u2019 orbitopathy: a systematic review and meta-analysis. Eye. 2025;39:1901\u201332. https:\/\/doi.org\/10.1038\/s41433-025-03845-8.","journal-title":"Eye"},{"key":"2388_CR13","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1210\/er.2018-00066","volume":"40","author":"TJ Smith","year":"2019","unstructured":"Smith TJ, Janssen JAMJL. Insulin-like growth factor-I receptor and thyroid-associated ophthalmopathy. Endocr Rev. 2019;40:236\u201367. https:\/\/doi.org\/10.1210\/er.2018-00066.","journal-title":"Endocr Rev"},{"key":"2388_CR14","doi-asserted-by":"publisher","first-page":"4397","DOI":"10.4049\/jimmunol.181.6.4397","volume":"181","author":"S Tsui","year":"2008","unstructured":"Tsui S, Naik V, Hoa N, Hwang CJ, Afifiyan NF, Sinha Hikim A, et al. Evidence for an association between thyroid-stimulating hormone and insulin-like growth factor 1 receptors: a tale of two antigens implicated in graves\u2019 disease. J Immunol. 2008;181:4397\u2013405. https:\/\/doi.org\/10.4049\/jimmunol.181.6.4397.","journal-title":"J Immunol"},{"key":"2388_CR15","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1007\/s40265-022-01804-1","volume":"82","author":"T Nie","year":"2022","unstructured":"Nie T, Lamb YN. Teprotumumab: a review in thyroid eye disease. Drugs. 2022;82:1663\u201370. https:\/\/doi.org\/10.1007\/s40265-022-01804-1.","journal-title":"Drugs"},{"key":"2388_CR16","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1080\/13543784.2020.1772752","volume":"29","author":"DH Slentz","year":"2020","unstructured":"Slentz DH, Nelson CC, Smith TJ. Teprotumumab: a novel therapeutic monoclonal antibody for thyroid-associated ophthalmopathy. Expert Opin Investig Drugs. 2020;29:645\u20139. https:\/\/doi.org\/10.1080\/13543784.2020.1772752.","journal-title":"Expert Opin Investig Drugs"},{"key":"2388_CR17","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1056\/NEJMoa1614949","volume":"376","author":"TJ Smith","year":"2017","unstructured":"Smith TJ, Kahaly GJ, Ezra DG, Fleming JC, Dailey RA, Tang RA, et al. Teprotumumab for thyroid-associated ophthalmopathy. N Engl J Med. 2017;376:1748\u201361. https:\/\/doi.org\/10.1056\/NEJMoa1614949.","journal-title":"N Engl J Med"},{"key":"2388_CR18","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1056\/NEJMoa1910434","volume":"382","author":"RS Douglas","year":"2020","unstructured":"Douglas RS, Kahaly GJ, Patel A, Sile S, Thompson EHZ, Perdok R, et al. Teprotumumab for the treatment of active thyroid eye disease. N Engl J Med. 2020;382:341\u201352. https:\/\/doi.org\/10.1056\/NEJMoa1910434.","journal-title":"N Engl J Med"},{"key":"2388_CR19","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s40265-020-01287-y","volume":"80","author":"A Markham","year":"2020","unstructured":"Markham A. Teprotumumab: first approval. Drugs. 2020;80:509\u201312. https:\/\/doi.org\/10.1007\/s40265-020-01287-y.","journal-title":"Drugs"},{"key":"2388_CR20","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.ophtha.2021.10.017","volume":"129","author":"RS Douglas","year":"2022","unstructured":"Douglas RS, Kahaly GJ, Ugradar S, Elflein H, Ponto KA, Fowler BT, et al. Teprotumumab efficacy, safety, and durability in longer-duration thyroid eye disease and re-treatment. Ophthalmology. 2022;129:438\u201349. https:\/\/doi.org\/10.1016\/j.ophtha.2021.10.017.","journal-title":"Ophthalmology"},{"key":"2388_CR21","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1210\/clinem\/dgad637","volume":"109","author":"RS Douglas","year":"2023","unstructured":"Douglas RS, Couch S, Wester ST, Fowler BT, Liu CY, Subramanian PS, et al. Efficacy and safety of teprotumumab in patients with thyroid eye disease of long duration and low disease activity. J Clin Endocrinol Metab. 2023;109:25\u201335. https:\/\/doi.org\/10.1210\/clinem\/dgad637.","journal-title":"J Clin Endocrinol Metab"},{"key":"2388_CR22","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1089\/thy.2023.0656","volume":"34","author":"GJ Kahaly","year":"2024","unstructured":"Kahaly GJ, Subramanian PS, Conrad E, Holt RJ, Smith TJ. Long-term efficacy of teprotumumab in thyroid eye disease: follow-up outcomes in three clinical trials. Thyroid. 2024;34:881\u20139. https:\/\/doi.org\/10.1089\/thy.2023.0656.","journal-title":"Thyroid"},{"key":"2388_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanwpc.2025.101464","volume":"55","author":"Y Hiromatsu","year":"2025","unstructured":"Hiromatsu Y, Ishikawa E, Kozaki A, Takahashi Y, Tanabe M, Hayashi K, et al. A randomised, double-masked, placebo-controlled trial evaluating the efficacy and safety of teprotumumab for active thyroid eye disease in Japanese patients. Lancet Reg Health West Pac. 2025;55:101464. https:\/\/doi.org\/10.1016\/j.lanwpc.2025.101464.","journal-title":"Lancet Reg Health West Pac."},{"key":"2388_CR24","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1001\/jamaophthalmol.2025.3350","volume":"143","author":"H Zhang","year":"2025","unstructured":"Zhang H, Sun J, Li Y, Zhu L, Shan Z, Lu W, et al. IGF-1R inhibitor IBI311 for the treatment of active thyroid eye disease in Chinese patients: the RESTORE-1 randomized clinical trial. JAMA Ophthalmol. 2025;143:964\u201372. https:\/\/doi.org\/10.1001\/jamaophthalmol.2025.3350.","journal-title":"JAMA Ophthalmol"},{"key":"2388_CR25","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1016\/j.ophtha.2026.04.022","volume":"133","author":"MT Yen","year":"2026","unstructured":"Yen MT, Cockerham K, Saeed P, Leibowitz S, Mudumbai RC, Schittkowski MP, et al. THRIVE: a phase 3, randomized, double-masked, placebo-controlled study of veligrotug for active thyroid eye disease. Ophthalmology. 2026;133:1085\u201396. https:\/\/doi.org\/10.1016\/j.ophtha.2026.04.022.","journal-title":"Ophthalmology"},{"key":"2388_CR26","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvaf149.2240","volume":"9","author":"AP Jain","year":"2025","unstructured":"Jain AP, Cockerham K, Abrams J, Mandeville J, Al Khudari M, Leibowitz S, et al. OR31-07 THRIVE-2 phase 3 trial of veligrotug (VRDN-001) in chronic thyroid eye disease (TED): efficacy and safety at 15 weeks. J Endocr Soc. 2025;9:bvaf149.2240. https:\/\/doi.org\/10.1210\/jendso\/bvaf149.2240.","journal-title":"J Endocr Soc"},{"key":"2388_CR27","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/d41573-026-00118-1","volume":"25","author":"A Mullard","year":"2026","unstructured":"Mullard A. FDA approves second IGF-1R-targeted antibody for thyroid eye disease. Nat Rev Drug Discov. 2026;25:583\u2013583. https:\/\/doi.org\/10.1038\/d41573-026-00118-1.","journal-title":"Nat Rev Drug Discov"},{"key":"2388_CR28","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2025.2585616","volume":"17","author":"R Kaplan","year":"2025","unstructured":"Kaplan R, Zhao Y, Tsai J, Dickinson B, Swanson T, Foster K, et al. Preclinical pharmacology, pharmacokinetics, and pharmacodynamics of veligrotug, a full antagonist antibody to the IGF-1 receptor in development for thyroid eye disease. MAbs. 2025;17:2585616. https:\/\/doi.org\/10.1080\/19420862.2025.2585616.","journal-title":"MAbs"},{"key":"2388_CR29","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.ophtha.2023.10.018","volume":"131","author":"SA Shah","year":"2024","unstructured":"Shah SA, Amarikwa L, Sears CM, Clauss KD, Rajjoub RD, Kang JY, et al. Teprotumumab-related adverse events in thyroid eye disease. Ophthalmology. 2024;131:458\u201367. https:\/\/doi.org\/10.1016\/j.ophtha.2023.10.018.","journal-title":"Ophthalmology"},{"key":"2388_CR30","doi-asserted-by":"publisher","first-page":"e654","DOI":"10.1210\/clinem\/dgad213","volume":"108","author":"MN Stan","year":"2023","unstructured":"Stan MN, Krieger CC. The adverse effects profile of teprotumumab. J Clin Endocrinol Metab. 2023;108:e654\u201362. https:\/\/doi.org\/10.1210\/clinem\/dgad213.","journal-title":"J Clin Endocrinol Metab"},{"key":"2388_CR31","doi-asserted-by":"publisher","DOI":"10.1530\/EC-25-0293","volume":"14","author":"MJL Barnett","year":"2025","unstructured":"Barnett MJL, Lam J, Jara-Tantoco MN, Casipit C, Eidbo S, Anastasopoulou C. Teprotumumab and sensorineural hearing loss: a propensity score-matched retrospective cohort study. Endocr Connect. 2025;14:e250293. https:\/\/doi.org\/10.1530\/EC-25-0293.","journal-title":"Endocr Connect"},{"key":"2388_CR32","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/j.ophtha.2024.01.023","volume":"131","author":"TJ Smith","year":"2024","unstructured":"Smith TJ, Cavida D, Hsu K, Kim S, Fu Q, Barbesino G, et al. Glycemic trends in patients with thyroid eye disease treated with teprotumumab in 3 clinical trials. Ophthalmology. 2024;131:815\u201326. https:\/\/doi.org\/10.1016\/j.ophtha.2024.01.023.","journal-title":"Ophthalmology"},{"key":"2388_CR33","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1097\/IOP.0000000000002569","volume":"40","author":"AK Terrarosa","year":"2024","unstructured":"Terrarosa AK, DeMaria LN, North VS, Garcia MD, Kim ET, Belinsky I. Menstrual irregularities and amenorrhea in thyroid eye disease patients treated with teprotumumab. Ophthal Plast Reconstr Surg. 2024;40:312\u20135. https:\/\/doi.org\/10.1097\/IOP.0000000000002569.","journal-title":"Ophthal Plast Reconstr Surg"},{"key":"2388_CR34","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2020","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2020;372:n71. https:\/\/doi.org\/10.1136\/bmj.n71.","journal-title":"BMJ"},{"key":"2388_CR35","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-016-0384-4","volume":"5","author":"M Ouzzani","year":"2016","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan\u2014a web and mobile app for systematic reviews. Syst Rev. 2016;5:210. https:\/\/doi.org\/10.1186\/s13643-016-0384-4.","journal-title":"Syst Rev"},{"key":"2388_CR36","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-5-13","volume":"5","author":"SP Hozo","year":"2005","unstructured":"Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol. 2005;5:13. https:\/\/doi.org\/10.1186\/1471-2288-5-13.","journal-title":"BMC Med Res Methodol"},{"key":"2388_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-14-135","volume":"14","author":"X Wan","year":"2014","unstructured":"Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range. BMC Med Res Methodol. 2014;14:135. https:\/\/doi.org\/10.1186\/1471-2288-14-135.","journal-title":"BMC Med Res Methodol"},{"key":"2388_CR38","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898.","journal-title":"BMJ"},{"key":"2388_CR39","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1136\/ebmental-2019-300117","volume":"22","author":"S Balduzzi","year":"2019","unstructured":"Balduzzi S, R\u00fccker G, Schwarzer G. How to perform a meta-analysis with R: a practical tutorial. Evid Based Ment Health. 2019;22:153\u201360. https:\/\/doi.org\/10.1136\/ebmental-2019-300117.","journal-title":"Evid Based Ment Health"},{"key":"2388_CR40","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","volume":"21","author":"JPT Higgins","year":"2002","unstructured":"Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539\u201358. https:\/\/doi.org\/10.1002\/sim.1186.","journal-title":"Stat Med"},{"key":"2388_CR41","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1002\/jrsm.12","volume":"1","author":"M Borenstein","year":"2010","unstructured":"Borenstein M, Hedges LV, Higgins JPT, Rothstein HR. A basic introduction to fixed-effect and random-effects models for meta-analysis. Res Synth Methods. 2010;1:97\u2013111. https:\/\/doi.org\/10.1002\/jrsm.12.","journal-title":"Res Synth Methods"},{"key":"2388_CR42","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1002\/jrsm.1348","volume":"10","author":"G Schwarzer","year":"2019","unstructured":"Schwarzer G, Chemaitelly H, Abu-Raddad LJ, R\u00fccker G. Seriously misleading results using inverse of freeman-tukey double arcsine transformation in meta-analysis of single proportions. Res Synth Methods. 2019;10:476\u201383. https:\/\/doi.org\/10.1002\/jrsm.1348.","journal-title":"Res Synth Methods"},{"key":"2388_CR43","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1136\/bjo.73.8.639","volume":"73","author":"MP Mourits","year":"1989","unstructured":"Mourits MP, Koornneef L, Wiersinga WM, Prummel MF, Berghout A, Van Der Gaag R. Clinical criteria for the assessment of disease activity in graves\u2019 ophthalmopathy: a novel approach. Br J Ophthalmol. 1989;73:639\u201344. https:\/\/doi.org\/10.1136\/bjo.73.8.639.","journal-title":"Br J Ophthalmol"},{"key":"2388_CR44","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1001\/jamaophthalmol.2021.6284","volume":"140","author":"RS Douglas","year":"2022","unstructured":"Douglas RS, Dailey R, Subramanian PS, Barbesino G, Ugradar S, Batten R, et al. Proptosis and diplopia response with teprotumumab and placebo vs the recommended treatment regimen with intravenous methylprednisolone in moderate to severe thyroid eye disease: a meta-analysis and matching-adjusted indirect comparison. JAMA Ophthalmol. 2022;140:328\u201335. https:\/\/doi.org\/10.1001\/jamaophthalmol.2021.6284.","journal-title":"JAMA Ophthalmol"},{"key":"2388_CR45","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1016\/j.ophtha.2025.05.012","volume":"132","author":"J-E Lo","year":"2025","unstructured":"Lo J-E, Freitag SK, Liu CY, Barbesino G, Ma KS-K. Long-term cardiovascular, renal, and safety outcomes of teprotumumab versus systemic glucocorticoids in thyroid eye disease. Ophthalmology. 2025;132:1142\u201351. https:\/\/doi.org\/10.1016\/j.ophtha.2025.05.012.","journal-title":"Ophthalmology"},{"key":"2388_CR46","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1160936","volume":"14","author":"Y Hu","year":"2023","unstructured":"Hu Y, Chen J, Lin K, Yu X. Efficacy and safety of intravenous monoclonal antibodies in patients with moderate-to-severe active graves\u2019 ophthalmopathy: a systematic review and meta-analysis. Front Endocrinol. 2023;14:1160936. https:\/\/doi.org\/10.3389\/fendo.2023.1160936.","journal-title":"Front Endocrinol"},{"key":"2388_CR47","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1097\/IOP.0000000000002563","volume":"40","author":"S Hubschman","year":"2024","unstructured":"Hubschman S, Sojitra B, Ghiam S, Sears C, Hwangbo N, Goldberg RA, et al. Teprotumumab and orbital decompression for the management of proptosis in patients with thyroid eye disease. Ophthal Plast Reconstr Surg. 2024;40:271\u20135. https:\/\/doi.org\/10.1097\/IOP.0000000000002563.","journal-title":"Ophthal Plast Reconstr Surg"},{"key":"2388_CR48","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1210\/clinem\/dgae877","volume":"110","author":"Y Xu","year":"2025","unstructured":"Xu Y, Liu R, Huang L, Qin Y, Liu W, Huang S, et al. Comprehensive comparisons of different treatments for active Graves orbitopathy: a systematic review and bayesian model\u2013based network meta-analysis. J Clin Endocrinol Metab. 2025;110:1792\u2013801. https:\/\/doi.org\/10.1210\/clinem\/dgae877.","journal-title":"J Clin Endocrinol Metab"},{"key":"2388_CR49","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvaf063","volume":"9","author":"GJ Kahaly","year":"2025","unstructured":"Kahaly GJ, Xi A, Barretto N, Patel H, Qashqai A, Shokoohi M, et al. Teprotumumab improves quality of life in thyroid eye disease: meta-analysis and matching-adjusted indirect comparison. J Endocr Soc. 2025;9:bvaf063. https:\/\/doi.org\/10.1210\/jendso\/bvaf063.","journal-title":"J Endocr Soc"},{"key":"2388_CR50","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.2147\/TCRM.S303057","volume":"17","author":"HM Teo","year":"2021","unstructured":"Teo HM, Smith TJ, Joseph SS. Efficacy and safety of teprotumumab in thyroid eye disease. Ther Clin Risk Manag. 2021;17:1219\u201330. https:\/\/doi.org\/10.2147\/TCRM.S303057.","journal-title":"Ther Clin Risk Manag"},{"key":"2388_CR51","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.1007\/s00417-025-06855-0","volume":"263","author":"Y Lustig-Barzelay","year":"2025","unstructured":"Lustig-Barzelay Y, Yagoda D, Zunz E, Hamed-Azzam S, Avisar I, Kehat-Ophir S, et al. Time to improvement following teprotumumab treatment of thyroid eye disease: real world experience. Graefes Arch Clin Exp Ophthalmol. 2025;263:2349\u201358. https:\/\/doi.org\/10.1007\/s00417-025-06855-0.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"2388_CR52","doi-asserted-by":"publisher","DOI":"10.1136\/bmjophth-2023-001515","volume":"9","author":"OM Bello","year":"2024","unstructured":"Bello OM, Druce M, Ansari E. Graves\u2019 ophthalmopathy: the clinical and psychosocial outcomes of different medical interventions\u2014a systematic review. BMJ Open Ophthalmol. 2024;9:e001515. https:\/\/doi.org\/10.1136\/bmjophth-2023-001515.","journal-title":"BMJ Open Ophthalmol"},{"key":"2388_CR53","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1159\/000508071","volume":"9","author":"E Hoppe","year":"2021","unstructured":"Hoppe E, Lee ACH, Hoppe D, Kahaly GJ. Predictive factors for changes in quality of life after steroid treatment for active moderate-to-severe graves\u2019 orbitopathy: a prospective trial. Eur Thyroid J. 2021;9:313\u201320. https:\/\/doi.org\/10.1159\/000508071.","journal-title":"Eur Thyroid J"},{"key":"2388_CR54","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/s41574-024-00995-9","volume":"20","author":"JA Brant","year":"2024","unstructured":"Brant JA, Kikkawa DO, Smith TJ. Hearing abnormalities in patients treated with teprotumumab. Nat Rev Endocrinol. 2024;20:381\u20132. https:\/\/doi.org\/10.1038\/s41574-024-00995-9.","journal-title":"Nat Rev Endocrinol"},{"key":"2388_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.heares.2025.109287","volume":"463","author":"K Yamahara","year":"2025","unstructured":"Yamahara K, Ohnishi H, Nakagawa T, Omori K, Yamamoto N. Insulin-like growth factor 1 protects cochlear outer hair cells against cisplatin. Hear Res. 2025;463:109287. https:\/\/doi.org\/10.1016\/j.heares.2025.109287.","journal-title":"Hear Res"},{"key":"2388_CR56","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1089\/thy.2023.0466","volume":"34","author":"RS Douglas","year":"2024","unstructured":"Douglas RS, Parunakian E, Tolentino J, Malkhasyan E, Geng J, Sherman M, et al. A prospective study examining audiometry outcomes following teprotumumab treatment for thyroid eye disease. Thyroid. 2024;34:134\u20137. https:\/\/doi.org\/10.1089\/thy.2023.0466.","journal-title":"Thyroid"},{"key":"2388_CR57","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.ophtha.2023.08.001","volume":"131","author":"JA Keen","year":"2024","unstructured":"Keen JA, Correa T, Pham C, Claussen AD, Hansen MR, Carter KD, et al. Frequency and patterns of hearing dysfunction in patients treated with teprotumumab. Ophthalmology. 2024;131:30\u20136. https:\/\/doi.org\/10.1016\/j.ophtha.2023.08.001.","journal-title":"Ophthalmology"},{"key":"2388_CR58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ajo.2022.02.015","volume":"240","author":"CM Sears","year":"2022","unstructured":"Sears CM, Azad AD, Amarikwa L, Pham BH, Men CJ, Kaplan DN, et al. Hearing dysfunction after treatment with teprotumumab for thyroid eye disease. Am J Ophthalmol. 2022;240:1\u201313. https:\/\/doi.org\/10.1016\/j.ajo.2022.02.015.","journal-title":"Am J Ophthalmol"},{"key":"2388_CR59","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1002\/ohn.174","volume":"168","author":"E Kay-Rivest","year":"2023","unstructured":"Kay-Rivest E, Belinsky I, Kozlova A, Byrd E, McMenomey SO, Jethanamest D. Prospective assessment of otologic adverse events due to teprotumumab: preliminary results. Otolaryngol Head Neck Surg. 2023;168:1164\u20139. https:\/\/doi.org\/10.1002\/ohn.174.","journal-title":"Otolaryngol Head Neck Surg"},{"key":"2388_CR60","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1038\/s41433-024-03531-1","volume":"39","author":"JC Markle","year":"2025","unstructured":"Markle JC, Johanis A, Shaia JK, Benito D, Talcott KE, Singh RP. Risk of audiologic side effects with teprotumumab treatment for thyroid eye disease: propensity matched analysis. Eye. 2025;39:1107\u201314. https:\/\/doi.org\/10.1038\/s41433-024-03531-1.","journal-title":"Eye"},{"key":"2388_CR61","doi-asserted-by":"publisher","first-page":"e566","DOI":"10.1097\/MAO.0000000000004260","volume":"45","author":"PP Huynh","year":"2024","unstructured":"Huynh PP, Saba E, Rivero A, Peralta R, Liang J. A biologic with otologic consequences: analysis of hearing loss and teprotumumab using the FDA adverse event reporting system. Otol Neurotol. 2024;45:e566\u20139. https:\/\/doi.org\/10.1097\/MAO.0000000000004260.","journal-title":"Otol Neurotol"},{"key":"2388_CR62","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1002\/lary.70045","volume":"136","author":"K Hori","year":"2026","unstructured":"Hori K, Wenger T, Davuluru S, Zhang-Nunes S, Choi JS. Otologic symptoms in patients treated with teprotumumab: a multi-institutional national cohort study. Laryngoscope. 2026;136:395\u2013402. https:\/\/doi.org\/10.1002\/lary.70045.","journal-title":"Laryngoscope"},{"key":"2388_CR63","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1111\/cen.14178","volume":"92","author":"K Matsuzawa","year":"2020","unstructured":"Matsuzawa K, Izawa S, Kato A, Fukaya K, Matsumoto K, Okura T, et al. Low signal intensities of MRI T1 mapping predict refractory diplopia in graves\u2019 ophthalmopathy. Clin Endocrinol (Oxf). 2020;92:536\u201344. https:\/\/doi.org\/10.1111\/cen.14178.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2388_CR64","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/S2213-8587(21)00056-5","volume":"9","author":"GJ Kahaly","year":"2021","unstructured":"Kahaly GJ, Douglas RS, Holt RJ, Sile S, Smith TJ. Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials. Lancet Diabetes Endocrinol. 2021;9:360\u201372. https:\/\/doi.org\/10.1016\/S2213-8587(21)00056-5.","journal-title":"Lancet Diabetes Endocrinol"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02388-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-026-02388-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02388-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T08:11:55Z","timestamp":1792829515000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-026-02388-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,24]]},"references-count":64,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["2388"],"URL":"https:\/\/doi.org\/10.1007\/s40265-026-02388-w","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,24]]},"assertion":[{"value":"28 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflicts of interest, except for TJS who has the following disclosures. He was issued patents for targeting IGF-1R as therapy for autoimmune diseases, including TAO, held by Lundquist Institute\/UCLA and University of Michigan; and is a consultant for Amgen (formerly Horizon), Viridian Therapeutics, Lundbeck, Argenx, Lassen Therapeutics, Minghui Pharmaceuticals, Bristol Myers Squibb, Arrowhead Pharma, Innovent Biologics, Ollin Bioscience, and Escient Pharma.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The data that support the findings of this study are available from the available published literature.","order":5,"name":"Ethics","label":"Data Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The data analysis was performed using publicly available statistical software. The analysis code is available from the corresponding author upon reasonable request.","order":6,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No AI tools were used in the drafting, editing, translation, summarization, data analysis, image generation, or other forms of assistance in the preparation of this article.","order":7,"name":"Ethics","label":"Artificial intelligence (AI) use","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"HYZ, HFZ, and TJS conceived and designed the study. HYZ, ZXZ, and TL performed the literature search, study selection, data extraction, and quality assessment. HYZ, ZXZ, and TL performed the statistical analysis and drafted the manuscript. TJS, HFZ, SPC, HJZ, and YWL critically revised the manuscript. All authors reviewed and approved the final version of the manuscript.","order":8,"name":"Ethics","label":"Author Contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}